Eurofins completes USD 400 million deal as Eurofins stock nears yearly high
Published on 10/19/2026 at 09:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSDeal, results and valuation
- The Element acquisition closed on October 1, 2026 and added 27 laboratories.
- Eurofins expanded its adjusted EBITDA margin by 1.30 percentage points in H1 2026.
- Eurofins stock trades at EUR 78.48 at 9:34 a.m. CEST on October 19, 2026.
- The nine-month trading update is scheduled for October 21, 2026.
Eurofins Scientific (ISIN FR0014000MR3) completed its USD 400 million acquisition of Element Materials Technology's North American Life Sciences Testing Services business on October 1, 2026, while the stock traded at EUR 78.48 at Lang & Schwarz on October 19, 2026 at 9:34 a.m. CEST. The closing was announced on October 2 by Eurofins. The transaction adds 27 laboratories, approximately 750 staff and expected 2026 revenue of more than USD 150 million.
What the deal changes
The acquired operations strengthen Eurofins' BioPharma and Life businesses in North America. The official release says the laboratories will join the group's existing network and benefit from its hub-and-spoke model, creating a concrete capacity expansion rather than a purely financial transaction.
Eurofins also completed the sale of its Electrical and Electronic Testing business to UL Solutions on October 1, 2026. Business Wire reported an enterprise value of EUR 575 million, with proceeds directed toward debt reduction, laboratory investment, digital solutions, share buybacks and acquisitions.
Three dates and figures
On July 20, 2026, Eurofins announced the USD 400 million Element transaction, and on October 1, 2026, the acquisition closed, according to Eurofins. On the same October 1 date, the group completed the EUR 575 million MET Labs divestment, according to Business Wire.
What comes next for Eurofins
Eurofins will publish its nine-month 2026 trading update before markets open on October 21, 2026, followed by an investor day in Amersfoort on October 23, 2026. Both dates are listed on the company's investor-relations page.
The latest reported operating picture is H1 2026. Eurofins said adjusted EBITDA margin expanded by 1.30 percentage points and earnings per share grew 29.00 percent during that period, according to its investor materials. That combination gives the October update two measurable tests: integration of the acquired network and continued margin expansion.
Stock stays near its yearly high
Eurofins stock traded at EUR 78.48 at Lang & Schwarz on October 19, 2026 at 9:34 a.m. CEST. The EUR 13.6 billion market capitalization and EUR 54.86 to EUR 79.22 52-week range place the price 0.93 percent below the high.
The further course of trading is shown by the continuously updated real-time quote of Eurofins stock.
Eurofins stock key facts
- Company: Eurofins Scientific SE
- ISIN: FR0014000MR3
- Ticker: ERF
- Primary exchange: Euronext Paris
- Price Lang & Schwarz (as of October 19, 2026, 9:34 a.m. CEST): EUR 78.48
- Market capitalization: EUR 13.6 billion (as of October 19, 2026)
- 52-week range: EUR 54.86-EUR 79.22 (as of October 19, 2026)
- Sector / Industry: Health Care / Analytical testing services
Market context: Market report CAC 40.
